Korro Bio Early Trial Results Fall Short; Stock Hits New Low

Benzinga11-14

Korro Bio, Inc. (NASDAQ:KRRO) stock is sinking on Thursday with a session volume of 6.68 million compared to the average volume of 1.42 million, as per data from Benzinga Pro. The genetic medicines ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2583524516?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/13/Medical-Development-Laboratory-Caucasian.jpeg?optimize=medium&dpr=2&auto=webp&width=260","is_english":true,"pubTime":"2025-11-14 03:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583524516","market":"nz","top_or_hot":-1,"title":"Korro Bio Early Trial Results Fall Short; Stock Hits New Low","media":"Benzinga","content":"<div>\n<p>Korro Bio, Inc. (NASDAQ:KRRO) stock is sinking on Thursday with a session volume of 6.68 million compared to the average volume of 1.42 million, as per data from Benzinga Pro.\nThe genetic medicines ...</p>\n\n<a href=\"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/11/48846497/korro-bio-early-trial-results-fall-short-stock-hits-new-low\">Source Link</a>\n\n</div>\n","source":"benzinga_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Korro Bio Early Trial Results Fall Short; Stock Hits New Low</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKorro Bio Early Trial Results Fall Short; Stock Hits New Low\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-14 03:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/11/48846497/korro-bio-early-trial-results-fall-short-stock-hits-new-low><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Korro Bio, Inc. (NASDAQ:KRRO) stock is sinking on Thursday with a session volume of 6.68 million compared to the average volume of 1.42 million, as per data from Benzinga Pro.\nThe genetic medicines ...</p>\n\n<a href=\"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/11/48846497/korro-bio-early-trial-results-fall-short-stock-hits-new-low\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4532","symbol_name":"文艺复兴科技持仓","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/11/48846497/korro-bio-early-trial-results-fall-short-stock-hits-new-low","article_id":"2583524516","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/13/Medical-Development-Laboratory-Caucasian.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/11/48846497/korro-bio-early-trial-results-fall-short-stock-hits-new-low","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2583524516","pubTimestamp":1763061960,"columns":[],"sourceInfo":{"source_id":"benzinga_hot_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Korro Bio shares drop after KRRO-110 trial in AATD misses protein goals; company cuts 34% of staff and shifts focus to liver-targeted programs.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4532":"文艺复兴科技持仓","BK4599":"减肥药","BK4007":"制药","BK4139":"生物科技","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4081":"电力公用事业","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","KRRO":"Korro Bio, Inc.","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4588":"碎股","HE":"夏威夷电力","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK4585":"ETF&股票定投概念","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1"},"translate_title":"Korro Bio早期试验结果未达预期；股价再创新低","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KRRO":1,"HE":1},"content_text":"Korro Bio, Inc. (NASDAQ:KRRO) stock is sinking on Thursday with a session volume of 6.68 million compared to the average volume of 1.42 million, as per data from Benzinga Pro.\nThe genetic medicines company provided a program update for its Phase 1/2a REWRITE clinical trial of KRRO-110 in alpha-1 antitrypsin deficiency (AATD).\nAAT deficiency is a genetic disorder where the body doesn't produce enough of the AAT protein, which protects the lungs and liver from damage.\nAlso Read: Sanofi Drug Shows Superior Efficacy In Genetic Disease Compared To Current Standard Therapy\nThe company announced that KRRO-110 generated functional M-AAT protein in AATD patients. While a single administration of KRRO-110 achieved functional protein production, it did not achieve the protein levels projected based on preclinical data.\nAcross five AATD patients in the two single ascending dose cohorts evaluable with turbidimetry, the greatest peak total AAT protein was approximately 10 µM, and the greatest increase of total AAT protein from baseline was approximately 3 µM.\nThe total AAT protein levels following single-dose administration did not reach the protective threshold of 11 µM.\nNo dose-limiting toxicities or treatment-emergent serious adverse events observed.\n\"To focus our resources on generating clinical data and advancing additional GalNAc-conjugated programs targeting the liver, we are implementing a strategic restructuring that reduces our workforce by approximately a third while extending our cash runway into the second half of 2027,\" said Ram Aiyar, CEO and President of Korro Bio.\nKorro has nominated KRRO-121 as its next development candidate for hyperammonemia, including patients with urea cycle disorders (UCD) and hepatic encephalopathy (HE).\nRegulatory filing to enable commencement of first-in-human trial for KRRO-121 is anticipated in the second half of 2026.\nKorro amended its research collaboration and license agreement with Novo Nordisk A/S (NYSE:NVO). This amendment establishes a 12-month pause to reassess the rationale for the current target under the first research program.\nKorro reduced its workforce by approximately 34%.\nCash, cash equivalents, and marketable securities were $102.5 million, extending the cash runway into the second half of 2027 by implementing a strategic restructuring.\nWilliam Blair downgraded Korro shares from Outperform to Market Perform.\nAnalyst Myles Minter said, \"On the one hand, the presence of M-AAT in AATD patients is yet another validation of viable ADAR-mediated editing in humans; on the other hand, the KRRO-110 clinical profile looks non-competitive at the moment.\"\nAnalyst Minter said, \"We are still believers in ADAR editing and are intrigued by Korro's expansion into urea cycle disorders with KRRO-121, but with Novo placing its collaboration on pause and Korro moving back to a preclinical-stage company, we are moving to the sidelines for now.\"\nPrice Action: KRRO stock is down 80% at $6.27 at the last check on Thursday.\nRead Next:\nPhoto via Shutterstock","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2583524516","isCrawlerRequest":true}